We must optimize stent deployment & maintain a registry of how well (or poorly) we use drug-eluting stents. Instead of asking “Which stent?” or “How much anti-platelet therapy?” we must ask “How effectively are we deploying our stents?”
Articles on the various questions, problems, and controversies currently plaguing drug-eluting stents: deployment techniques, stent qualities, antiplatelet therapies, and etiologies of post-DES thrombosis and restenosis.
Two Swiss meta-analyses have found an increased rate of myocardial infarction and death with the Cypher (sirolimus-eluting) coronary stent, which is likely to put a serious chill in interventional cardiology's infatuation with drug-coated devices